J Clin Oncol 21 (8): 1431-9, 2003.[PUBMED Abstract] Hudis C, Citron M, Berry D, et al.: Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective.
[Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-41, 2005.
Citron ML, Berry DA, Cirrincione C, et al.: Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD treatment: update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG.
[Abstract] J Clin Oncol 23 (Suppl 16): A-620, 33s, 2005.
Del Mastro L, De Placido S, Bruzzi P, et al.: Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 Ã— 2 factorial, randomised phase 3 trial.